Unveiling key financial outcomes and strategic milestones, Capricor Therapeutics sets a robust path for 2024.
Explore the key financial outcomes and strategic insights from Stereotaxis Inc's first quarter of 2024, reflecting both progress and hurdles.
Discover how Voyager Therapeutics Inc (VYGR) is advancing its neurogenetic medicine pipeline and strengthening financial stability through strategic collaborations.
Thru | Total | Purse | ||
---|---|---|---|---|
F | -24 | $450,000 | ||
F | -22 | $277,738 | ||
F | -9 | $201,479 | ||
F | -8 | $127,984 | ||
F | -8 | $127,984 | ||
F | -8 | $127,984 | ||
F | -7 | $69,492 | ||
F | -7 | $69,492 | ||
F | -7 | $69,492 | ||
F | -7 | $69,492 |